{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T17:04:28Z","timestamp":1758906268677},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,9,14]],"date-time":"2010-09-14T00:00:00Z","timestamp":1284422400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1007\/s00198-010-1380-5","type":"journal-article","created":{"date-parts":[[2010,9,13]],"date-time":"2010-09-13T18:15:29Z","timestamp":1284401729000},"page":"1927-1934","source":"Crossref","is-referenced-by-count":12,"title":["Effects of raloxifene and alendronate on bone turnover as assessed by procollagen type I N-terminal propeptide"],"prefix":"10.1007","volume":"22","author":[{"given":"R.","family":"Eastell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. H.","family":"Krege","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,9,14]]},"reference":[{"key":"1380_CR1","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0021-9290(85)90204-0","volume":"18","author":"DB Burr","year":"1985","unstructured":"Burr DB, Martin RB, Schaffler MB, Radin EL (1985) Bone remodeling in response to in vivo fatigue microdamage. J Biomech 18:189\u2013200","journal-title":"J Biomech"},{"key":"1380_CR2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1210\/er.23.3.279","volume":"23","author":"BL Riggs","year":"2002","unstructured":"Riggs BL, Khosla S, Melton LJ 3rd (2002) Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 23:279\u2013302","journal-title":"Endocr Rev"},{"key":"1380_CR3","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1359\/jbmr.2000.15.4.621","volume":"15","author":"RS Weinstein","year":"2000","unstructured":"Weinstein RS (2000) True strength. J Bone Miner Res 15:621\u2013625","journal-title":"J Bone Miner Res"},{"key":"1380_CR4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1359\/JBMR.041114","volume":"20","author":"BL Riggs","year":"2005","unstructured":"Riggs BL, Parfitt AM (2005) Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res 20:177\u2013184","journal-title":"J Bone Miner Res"},{"key":"1380_CR5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1017\/S002966510800699X","volume":"67","author":"R Eastell","year":"2008","unstructured":"Eastell R, Hannon RA (2008) Biomarkers of bone health and osteoporosis risk. Proc Nutr Soc 67:157\u2013162","journal-title":"Proc Nutr Soc"},{"key":"1380_CR6","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1210\/jc.79.6.1693","volume":"79","author":"P Garnero","year":"1994","unstructured":"Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD (1994) Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693\u20131700","journal-title":"J Clin Endocrinol Metab"},{"key":"1380_CR7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1185\/030079905X75096","volume":"22","author":"R Eastell","year":"2006","unstructured":"Eastell R, Krege JH, Chen P, Glass EV, Reginster JY (2006) Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin 22:61\u201366","journal-title":"Curr Med Res Opin"},{"key":"1380_CR8","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00198-009-0838-9","volume":"20","author":"R Civitelli","year":"2009","unstructured":"Civitelli R, Armamento-Villareal R, Napoli N (2009) Bone turnover markers: understanding their value in clinical trials and clinical practice. Osteoporos Int 20:843\u2013851","journal-title":"Osteoporos Int"},{"key":"1380_CR9","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1093\/clinchem\/42.6.947","volume":"42","author":"J Melkko","year":"1996","unstructured":"Melkko J, Kauppila S, Niemi S, Risteli L, Haukipuro K, Jukkola A, Risteli J (1996) Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin Chem 42:947\u2013954","journal-title":"Clin Chem"},{"issue":"Suppl 6","key":"1380_CR10","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1007\/s001980070004","volume":"11","author":"R Hannon","year":"2000","unstructured":"Hannon R, Eastell R (2000) Preanalytical variability of biochemical markers of bone turnover. Osteoporos Int 11(Suppl 6):S30\u2013S44","journal-title":"Osteoporos Int"},{"key":"1380_CR11","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1359\/jbmr.1998.13.7.1124","volume":"13","author":"R Hannon","year":"1998","unstructured":"Hannon R, Blumsohn A, Naylor K, Eastell R (1998) Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res 13:1124\u20131133","journal-title":"J Bone Miner Res"},{"key":"1380_CR12","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/S0140-6736(06)68891-0","volume":"367","author":"P Sambrook","year":"2006","unstructured":"Sambrook P, Cooper C (2006) Osteoporosis. Lancet 367:2010\u20132018","journal-title":"Lancet"},{"key":"1380_CR13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11926-003-0085-6","volume":"5","author":"AA Reszka","year":"2003","unstructured":"Reszka AA, Rodan GA (2003) Bisphosphonate mechanism of action. Curr Rheumatol Rep 5:65\u201374","journal-title":"Curr Rheumatol Rep"},{"key":"1380_CR14","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1056\/NEJM199712043372301","volume":"337","author":"PD Delmas","year":"1997","unstructured":"Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641\u20131647","journal-title":"N Engl J Med"},{"key":"1380_CR15","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/01.GME.0000119981.77837.1F","volume":"11","author":"M Luckey","year":"2004","unstructured":"Luckey M, Kagan R, Greenspan S, Bone H, Kiel RD, Simon J, Sackarowitz J, Palmisano J, Chen E, Petruschke RA, de Papp AE (2004) Once-weekly alendronate 70\u00a0mg and raloxifene 60\u00a0mg daily in the treatment of postmenopausal osteoporosis. Menopause 11:405\u2013415","journal-title":"Menopause"},{"key":"1380_CR16","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1359\/jbmr.2000.15.1.129","volume":"15","author":"KE Naylor","year":"2000","unstructured":"Naylor KE, Iqbal P, Fledelius C, Fraser RB, Eastell R (2000) The effect of pregnancy on bone density and bone turnover. J Bone Miner Res 15:129\u2013137","journal-title":"J Bone Miner Res"},{"key":"1380_CR17","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00198-008-0672-5","volume":"20","author":"JS Walsh","year":"2009","unstructured":"Walsh JS, Henry YM, Fatayerji D, Eastell R (2009) Lumbar spine peak bone mass and bone turnover in men and women: a longitudinal study. Osteoporos Int 20:355\u2013362","journal-title":"Osteoporos Int"},{"key":"1380_CR18","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"B Ettinger","year":"1999","unstructured":"Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637\u2013645","journal-title":"JAMA"},{"key":"1380_CR19","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.bone.2003.10.004","volume":"34","author":"JY Reginster","year":"2004","unstructured":"Reginster JY, Sarkar S, Zegels B, Henrotin Y, Bruyere O, Agnusdei D, Collette J (2004) Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 34:344\u2013351","journal-title":"Bone"},{"key":"1380_CR20","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1001\/archinte.165.15.1762","volume":"165","author":"MR McClung","year":"2005","unstructured":"McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, Donley DW, Dalsky GP, Eriksen EF (2005) Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 165:1762\u20131768","journal-title":"Arch Intern Med"},{"key":"1380_CR21","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1359\/jbmr.040117","volume":"19","author":"B Ettinger","year":"2004","unstructured":"Ettinger B, San Martin J, Crans G, Pavo I (2004) Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19:745\u2013751","journal-title":"J Bone Miner Res"},{"key":"1380_CR22","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1210\/jc.2002-020334","volume":"87","author":"JJ Body","year":"2002","unstructured":"Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, Dore RK, Correa-Rotter R, Papaioannou A, Cumming DC, Hodsman AB (2002) A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1\u201334)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87:4528\u20134535","journal-title":"J Clin Endocrinol Metab"},{"key":"1380_CR23","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4899-3324-9","volume-title":"Density estimation for statistics and data analysis. In: Monographs on statistics and applied probability","author":"BW Silverman","year":"1986","unstructured":"Silverman BW (1986) Density estimation for statistics and data analysis. In: Monographs on statistics and applied probability. Chapman and Hall, London"},{"key":"1380_CR24","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1210\/jc.2004-2212","volume":"91","author":"D Michalska","year":"2006","unstructured":"Michalska D, Stepan JJ, Basson BR, Pavo I (2006) The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 91:870\u2013877","journal-title":"J Clin Endocrinol Metab"},{"key":"1380_CR25","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1210\/jc.87.3.985","volume":"87","author":"O Johnell","year":"2002","unstructured":"Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E (2002) Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87:985\u2013992","journal-title":"J Clin Endocrinol Metab"},{"key":"1380_CR26","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1359\/JBMR.040512","volume":"19","author":"DC Bauer","year":"2004","unstructured":"Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD, Fracture Intervention Trial Study Group (2004) Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 19:1250\u20131258","journal-title":"J Bone Miner Res"},{"key":"1380_CR27","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1210\/jc.87.4.1586","volume":"87","author":"MC Hochberg","year":"2002","unstructured":"Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD (2002) Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87:1586\u20131592","journal-title":"J Clin Endocrinol Metab"},{"key":"1380_CR28","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMc0707493","volume":"358","author":"BA Lenart","year":"2008","unstructured":"Lenart BA, Lorich DG, Lane JM (2008) Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 358:1304\u20131306","journal-title":"N Engl J Med"},{"key":"1380_CR29","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1359\/jbmr.081247","volume":"24","author":"B Abrahamsen","year":"2009","unstructured":"Abrahamsen B, Eiken P, Eastell R (2009) Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 24:1095\u20131102","journal-title":"J Bone Miner Res"},{"key":"1380_CR30","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1615\/CritRevEukarGeneExpr.v19.i1.40","volume":"19","author":"T Martin","year":"2009","unstructured":"Martin T, Gooi JH, Sims NA (2009) Molecular mechanisms in coupling of bone formation to resorption. Crit Rev Eukaryot Gene Expr 19:73\u201388","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"1380_CR31","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.bone.2009.07.089","volume":"45","author":"A Rogers","year":"2009","unstructured":"Rogers A, Glover SJ, Eastell R (2009) A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy. Bone 45:1044\u20131052","journal-title":"Bone"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-010-1380-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-010-1380-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-010-1380-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T15:26:54Z","timestamp":1591889214000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-010-1380-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,14]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["1380"],"URL":"https:\/\/doi.org\/10.1007\/s00198-010-1380-5","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,14]]}}}